{'fraction_non_alphanumeric': 0.013445378151260505, 'fraction_numerical': 0.013445378151260505, 'mean_word_length': 6.095238095238095, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A proficiency testing study to evaluate laboratory performance for the detection of different genotypes of parvovirus B19

Background and Objectives  In Europe, it is a regulatory requirement that parvovirus B19 (B19V) DNA nucleic acid amplification technique‐based testing is performed on plasma pools for certain classes of plasma‐derived medicinal products. This proficiency testing study set out to examine the ability of public quality control laboratories and plasma fractionation organizations to detect different genotypes of B19V using nucleic acid amplification technique‐based assays.